CASI News and Press, CASI Pharmaceuticals Inc. From 08/23/21

Trillium Therapeutics (NASDAQ:TRIL) +191% after acquisition by Pfizer for $2.3B Vivos Therapeutics (NASDAQ:VVOS) +61% on FDA 510k clearance for sleep apnea treatment device Xeris Pharmaceuticals (NASDAQ:XERS) +48% announces approval of supplemental new drug Application (sN...

A major legal setback for gig employers took center stage in Monday's pre-market trading. Uber (NYSE:UBER), Lyft (NASDAQ:LYFT) and DoorDash (NYSE:DASH) all lost ground after a key California law was declared unconstitutional. Elsewhere, Richard Branson is taking another space-centered enterpr...

CASI Pharmaceuticals, Inc. (CASI) Q2 2021 Earnings Conference Call August 12, 2021 08:00 AM ET Company Participants Cynthia Hu - General Counsel & Secretary Wei-Wu He - Chairman & Chief Executive Officer Larry Zhang - President Alex Zukiwski - Chief Medical Officer Jim Goldschmidt - S...

CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results - EVOMELA Second Quarter 2021 Revenue Continues Upward Trend; Revenue Growth Guidance in 2021 Revised to Exceed 80% Over 2020 - - CID-103 Reaches Milestone with Dosing of First Patient - - Notice of Pat...

CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021 PR Newswire ROCKVILLE, Md. and BEIJING , Aug. 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical comp...

Shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) traded today at $1.14, breaking its 52-week low. This new low was reached on below average trading volume as 167,000 shares traded hands, while the average 30-day volume is approximately 954,000 shares. Based on a current price of $1.19, ...

China-based venture capital firm Qiming has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial regional focus on Greater China and Asia. Shanghai Junshi Bio formed an mRNA Joint Venture with Hang...

Shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) traded at a new 52-week low today of $1.27. This new low was reached on below average trading volume as 167,000 shares traded hands, while the average 30-day volume is approximately 1.1 million shares. CASI Pharmaceuticals Inc is a biopha...

Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...

CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma PR Newswire ROCKVILLE, Md. and BEIJING , June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. b...